Descriptions:
Algovibes presents a large-scale systematic backtesting study covering the full Russell 1000 universe — 1,014 stocks, 66 technical trading strategies, and approximately 4 million total parameter combinations explored via Bayesian optimization, which focuses the search on productive parameter regions rather than testing exhaustively. Of the 2.3 million tests that produced enough trades to be statistically meaningful, 11,454 passed walk-forward validation across five sequential data windows, and 2,226 cleared all final filters: out-of-sample Sharpe between 0.5 and 2.5, maximum drawdown no worse than -35%, and at least 30 trades.
What separates this video from typical backtesting content is its transparency about methodology limitations. The presenter explicitly names four sources of bias: survivorship bias from using the current Russell 1000 membership list, look-ahead bias from testing 2015 data on stocks that grew into the index over the following decade, optimistic short execution assumptions due to variable borrow costs, and fixed-slippage execution models that don’t reflect real fill dynamics at scale. None of these invalidate the results, but they bound what the findings can claim.
Healthcare emerges as the dominant sector among verified strategies, with volatility and volume breakout patterns appearing consistently across names like UnitedHealth, Humana, Molina, Centene, and Cigna. The top individual result — a volatility breakout strategy on Omnicell — posts an out-of-sample Sharpe ratio of 1.89, 53% CAGR on out-of-sample windows, -14% maximum drawdown, and 163 trades. The full notebook, database, and pipeline are available to channel members for independent reproduction.
📺 Source: Algovibes · Published June 09, 2026
🏷️ Format: Benchmark Test
